Q-omics provides the consensus-scored KBTBD11 profile across patient tissues and cancer cell-line models. KBTBD11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KBTBD11 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, KBTBD11 protein abundance shows 28,812 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where KBTBD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD11 survival associations across molecular data types. KBTBD11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD11 RNA expression–survival associations across cancer types. High KBTBD11 expression shows unfavorable associations in LUSC, but favorable associations in KIRP, KIRC, READ, HNSC and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KBTBD11 RNA expression.
This table summarizes KBTBD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KBTBD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD11 shows lower tumor expression in KICH, THCA, COAD, LIHC and UCEC and higher tumor expression in KIRC. The KICH box plot shows higher KBTBD11 RNA expression in normal versus tumor tissue (log2 FC = −4.180, t-test p < 0.001).
This table shows molecular features associated with KBTBD11 in patient tissues and cancer cell lines. In patient samples, KBTBD11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KBTBD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
